# Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
Canonical URL: https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update
Ticker: FHTX
Company: Foghorn Therapeutics
Source: Foghorn Therapeutics
Published: 2026-05-07 11:00 EST
Original Source URL: https://ir.foghorntx.com
## Summary

- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory  - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND

## Article Body
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory  - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND
## Recent Company News
- 2026-05-12 11:00 EST — [Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may) — Source: Foghorn Therapeutics
- 2026-05-07 11:00 EST — [Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update) — Source: Foghorn Therapeutics
- 2026-04-21 20:05 EST — [Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-04-09 11:00 EST — [Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting) — Source: Foghorn Therapeutics
- 2026-03-11 20:10 EST — [Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook](https://biopharmsignal.com/news/FHTX/foghorn-therapeutics-provides-financial-update-for-2025-and-2026-strategic-outlook) — Source: Foghorn Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)